Open Access

Nucleobindin‑2 enhances the epithelial‑mesenchymal transition in renal cell carcinoma

  • Authors:
    • Ran Tao
    • Wen‑Bin Niu
    • Peng‑Hui Dou
    • Shao‑Bin Ni
    • Yi‑Peng Yu
    • Li‑Cheng Cai
    • Xin‑Yuan Wang
    • Shu‑Yi Li
    • Cheng Zhang
    • Zhen‑Guo Luo
  • View Affiliations

  • Published online on: April 10, 2020     https://doi.org/10.3892/ol.2020.11526
  • Pages: 3653-3664
  • Copyright: © Tao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Nucleobindin 2 (NUCB‑2) is a multifunctional protein that contains several functional domains and is associated with a wide variety of biological processes, such as food intake and energy homeostasis. NUCB‑2 has been demonstrated to be associated with worse malignant outcomes and cell migration in breast and prostate cancer. However, to the best of our knowledge, its clinical and biological significance in renal cell carcinoma remains unknown. In the present study, tissue specimens from 68 patients with renal cell carcinoma and 10 normal controls were collected for NUCB‑2 mRNA and protein assays. The NUCB‑2 level in the patients with renal cell cancer was significantly increased compared with the normal control patients. NUCB‑2‑knockout in the renal cancer cell line SK‑RC‑52 inhibited migration and invasion. In addition, the expression levels of molecules associated with epithelial‑mesenchymal transition (EMT), including E‑cadherin, β‑catenin, Slug and Twist, were affected by NUCB‑2 suppression and the zinc finger E‑box binding to homeobox 1 (ZEB1)‑dependent pathway. The AMP‑dependent protein kinase (AMPK)/target of rapamycin complex (mTORC) 1 signaling pathway participates in the regulation of NUCB‑2‑mediated metastasis and EMT. Suppression of NUCB‑2 also inhibited tumor nodule formation in a murine renal cell carcinoma tumor model. In summary, NUCB‑2 increased migration, invasion and EMT in renal cell carcinoma cells through the AMPK/TORC1/ZEB1 pathway in vitro and in vivo.
View Figures
View References

Related Articles

Journal Cover

June-2020
Volume 19 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tao R, Niu WB, Dou PH, Ni SB, Yu YP, Cai LC, Wang XY, Li SY, Zhang C, Luo ZG, Luo ZG, et al: Nucleobindin‑2 enhances the epithelial‑mesenchymal transition in renal cell carcinoma. Oncol Lett 19: 3653-3664, 2020
APA
Tao, R., Niu, W., Dou, P., Ni, S., Yu, Y., Cai, L. ... Luo, Z. (2020). Nucleobindin‑2 enhances the epithelial‑mesenchymal transition in renal cell carcinoma. Oncology Letters, 19, 3653-3664. https://doi.org/10.3892/ol.2020.11526
MLA
Tao, R., Niu, W., Dou, P., Ni, S., Yu, Y., Cai, L., Wang, X., Li, S., Zhang, C., Luo, Z."Nucleobindin‑2 enhances the epithelial‑mesenchymal transition in renal cell carcinoma". Oncology Letters 19.6 (2020): 3653-3664.
Chicago
Tao, R., Niu, W., Dou, P., Ni, S., Yu, Y., Cai, L., Wang, X., Li, S., Zhang, C., Luo, Z."Nucleobindin‑2 enhances the epithelial‑mesenchymal transition in renal cell carcinoma". Oncology Letters 19, no. 6 (2020): 3653-3664. https://doi.org/10.3892/ol.2020.11526